I-SPY 2 TRIAL Sites
Nineteen sites are open and accruing patients; the lead site is the University of California, San Francisco.
Please see below for the complete list of sites participating in I-SPY 2.
Find the latest information on open locations for the I-SPY2 TRIAL at ClinicalTrials.gov.
Current I-SPY 2 Site Locations:
- Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA
- Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
- University of Minnesota Medical Center, Minneapolis, MN
- University of Colorado Cancer Center, Aurora, CO
- Moores Cancer Center, University of California, San Diego, La Jolla, CA
- Inova Health System, Falls Church, VA
- The USC/Norris Comprehensive Cancer Center, The University of Southern California, Los Angeles, CA
- Arizona Cancer Center, The University of Arizona, Tucson, AZ
- Cardinal Bernardin Cancer Center, Loyola University Health System, Maywood, IL
- The Georgetown Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC
- Mayo Clinic, Scottsdale, AZ
- Mayo Clinic, Rochester, MN
- OHSU Knight Cancer Institute, Oregon Health and Science University, Portland, OR
- Swedish Cancer Institute, Swedish Medical Center, Seattle, WA
- The Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX
- The University of Chicago Cancer Research Center, Chicago, IL
I-SPY 2
is sponsored by the Biomarkers Consortium, a unique public-private partnership led by the Foundation for the National Institutes of Health that includes the Food and Drug Administration (FDA), the National Institutes of Health (NIH), and a large number of partners from major pharmaceutical companies, leading academic medical centers, non-profit and patient advocacy groups.
